Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current development of podophyllotoxins.

Literature DB >> 7044596

Current development of podophyllotoxins.

R Canetta, P Hilgard, S Florentine, P Bedogni, L Lenaz.

Abstract

The unique biological properties and therapeutic efficacy of the podophyllotoxin derivatives, Vumon (VM26, teniposide) and Vepesid (VP16-213, etoposide), are stimulating the interest of both laboratory and clinical researchers. Investigations on new pharmaceutical formulations, pharmacokinetics and metabolism are providing more appropriate information in drug administration; experimental chemotherapy indicates that, among others, cytosine arabinoside and cisplatin are highly synergistic with podophyllotoxins; single agent and combination treatment clinical trials are defining the respective role of Vumon and Vepesid in cancer chemotherapy.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1982 PMID： 7044596 DOI： 10.1007/bf00254528

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

35 in total

1. PHASE I clinical trial of an oral solution of VP-16-213.

Authors: N I Nissen; P Dombernowsky; H H Hansen; V Larsen
Journal: Cancer Treat Rep Date: 1976-07

2. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.

Authors: P Dombernowsky; N I Nissen
Journal: Eur J Cancer Date: 1976-03 Impact factor: 9.162

3. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors: F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal: Cancer Treat Rep Date: 1978-03

4. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

Authors: N I Nissen; V Larsen; H Pedersen; K Thomsen
Journal: Cancer Chemother Rep Date: 1972-12

5. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

Authors: R J Strife; I Jardine; M Colvin
Journal: J Chromatogr Date: 1980-05-09

6. PTG, a new antineoplastic epipodyphyllotoxin.

Authors: P J Creaven; L M Allen
Journal: Clin Pharmacol Ther Date: 1975-08 Impact factor: 6.875

7. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors: F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal: Cancer Treat Rep Date: 1979 Sep-Oct

8. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.

Authors: B F Issell; C Tihon; M E Curry
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

Review 9. Podophyllotoxin derivative VP 16-213.

Authors: A M Arnold
Journal: Cancer Chemother Pharmacol Date: 1979 Impact factor: 3.333

10. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.

Authors: A Goldhirsch; R A Joss; F Cavalli; R W Sonntag; K W Brunner
Journal: Med Pediatr Oncol Date: 1981

9 in total

1. Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.

Authors: D J Stewart; Z Grahovac; H Hugenholtz; V DaSilva; M T Richard; B Benoit; G Belanger; N Russell
Journal: J Neurooncol Date: 1993-07 Impact factor: 4.130

Current development of podophyllotoxins.

1. PHASE I clinical trial of an oral solution of VP-16-213.

2. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.

3. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

4. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

5. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

6. PTG, a new antineoplastic epipodyphyllotoxin.

7. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

8. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.

Review 9. Podophyllotoxin derivative VP 16-213.

10. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.

1. Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.

2. The effect of dose on the bioavailability of oral etoposide.

3. Synthesis of novel spin-labeled podophyllotoxin derivatives as potential antineoplastic agents: Part XXV.

Review 4. Pharmacokinetics of anticancer drugs in children.

5. Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

Review 6. The clinical pharmacology of etoposide and teniposide.

Review 7. Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents.

8. Stability of the i.v. and oral formulations of etoposide in solution.

9. Mechanistic analysis of carbon-carbon bond formation by deoxypodophyllotoxin synthase.